FierceBiotech· @FierceBiotech · X·· 2 天前精选AI 评分72
AI 导读
第一三共与默沙东在FDA表示其数据不足以支持在肺癌人群中的加速批准后，撤回了该ADC的上市申请。此举被视为对双方一笔40亿美元交易的又一打击。$MRK
推荐理由
FDA以数据不足为由拒绝加速批准后，双方撤回肺癌ADC上市申请，读者可了解该4B交易受挫的具体环节。
正文
Daiichi and Merck withdrew an ADC filing after the FDA said they lacked the data for accelerated approval in a lung cancer population. https://www.fiercebiotech.com/biotech/merck-co-and-daiichi-pull-lung-cancer-filing-after-fda-pushback-deals-another-blow-4b-deal $MRK
来源：FierceBiotech · x.com